Placebo administration for dry eye disease: a level I evidence based systematic review and meta-analysis.
Dry eye disease
Keratoconjunctivitis sicca
Placebo
Xerophthalmus
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
04
12
2021
accepted:
04
06
2022
pubmed:
9
8
2022
medline:
2
11
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
The efficacy of various common treatment options for dry eye disease (DED) has been investigated against placebo. However, the potential beneficial effect of placebo in the management of DED is still unclear. This meta-analysis investigated the impact of placebo administration in DED in Ocular Surface Disease Index (OSDI), Schirmer I test (SIT), tear breakup time (TBUT), corneal staining, and complications. This meta-analysis and systematic review was conducted according to the 2020 PRISMA guidelines. In March 2022, Pubmed, Web of Science, Google Scholar, and Embase were accessed. All the randomised clinical trials which investigated any active treatment against a placebo control group were considered. The following data were extracted at baseline and at last follow-up: Ocular Surface Disease Index (OSDI), tear breakup time test (TBUT), Schirmer I test (SIT), corneal staining. Data from 56 studies (12,205 patients) were retrieved. Placebo administration is not effective in improving TBUT (P = 0.3), OSDI (P = 0.2), SIT (P = 0.1) and corneal staining (P = 0.1) from baseline to last follow-up. Active treatment led to a higher TBUT and SIT compared to placebo administration (P < 0.0001). The active treatment resulted in a lower OSDI compared to placebo administration (P = 0.0005). Five studies reported data on the corneal staining. No difference was found between placebo administration and active treatment (P = 0.8). Placebo administration does not impact symptoms of DED and can be successfully employed to evaluate the efficacy of active treatments.
Sections du résumé
BACKGROUND
BACKGROUND
The efficacy of various common treatment options for dry eye disease (DED) has been investigated against placebo. However, the potential beneficial effect of placebo in the management of DED is still unclear.
AIM
OBJECTIVE
This meta-analysis investigated the impact of placebo administration in DED in Ocular Surface Disease Index (OSDI), Schirmer I test (SIT), tear breakup time (TBUT), corneal staining, and complications.
METHOD
METHODS
This meta-analysis and systematic review was conducted according to the 2020 PRISMA guidelines. In March 2022, Pubmed, Web of Science, Google Scholar, and Embase were accessed. All the randomised clinical trials which investigated any active treatment against a placebo control group were considered. The following data were extracted at baseline and at last follow-up: Ocular Surface Disease Index (OSDI), tear breakup time test (TBUT), Schirmer I test (SIT), corneal staining.
RESULTS
RESULTS
Data from 56 studies (12,205 patients) were retrieved. Placebo administration is not effective in improving TBUT (P = 0.3), OSDI (P = 0.2), SIT (P = 0.1) and corneal staining (P = 0.1) from baseline to last follow-up. Active treatment led to a higher TBUT and SIT compared to placebo administration (P < 0.0001). The active treatment resulted in a lower OSDI compared to placebo administration (P = 0.0005). Five studies reported data on the corneal staining. No difference was found between placebo administration and active treatment (P = 0.8).
CONCLUSION
CONCLUSIONS
Placebo administration does not impact symptoms of DED and can be successfully employed to evaluate the efficacy of active treatments.
Identifiants
pubmed: 35939178
doi: 10.1007/s11096-022-01439-y
pii: 10.1007/s11096-022-01439-y
pmc: PMC9618542
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1087-1101Informations de copyright
© 2022. The Author(s).
Références
Alshamrani AA, Almousa AS, Almulhim AA, et al. Prevalence and risk factors of dry eye symptoms in a Saudi Arabian population. Middle East Afr J Ophthalmol. 2017;24(2):67–73.
pubmed: 28936049
pmcid: 5598305
doi: 10.4103/meajo.MEAJO_281_16
Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802–12.
pubmed: 28797892
doi: 10.1016/j.jtos.2017.08.003
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–83.
pubmed: 28736335
doi: 10.1016/j.jtos.2017.05.008
Ohashi Y, Ishida R, Kojima T, et al. Abnormal protein profiles in tears with dry eye syndrome. Am J Ophthalmol. 2003;136(2):291–9.
pubmed: 12888052
doi: 10.1016/S0002-9394(03)00203-4
Javadi MA, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011;6(3):192–8.
pubmed: 22454735
pmcid: 3306104
Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye syndrome: summary of a Cochrane systematic review. Br J Ophthalmol. 2019;103(3):301–6.
pubmed: 30337332
doi: 10.1136/bjophthalmol-2018-313267
Deinema LA, Vingrys AJ, Wong CY, et al. A randomized, double-masked, placebo-controlled clinical trial of two forms of omega-3 supplements for treating dry eye disease. Ophthalmology. 2017;124(1):43–52.
pubmed: 27817918
doi: 10.1016/j.ophtha.2016.09.023
Mencucci R, Boccalini C, Caputo R, et al. Effect of a hyaluronic acid and carboxymethylcellulose ophthalmic solution on ocular comfort and tear-film instability after cataract surgery. J Cataract Refract Surg. 2015;41(8):1699–704.
pubmed: 26432128
doi: 10.1016/j.jcrs.2014.12.056
Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology. 2012;119(12):2471–8.
pubmed: 23009892
doi: 10.1016/j.ophtha.2012.06.052
Ang BCH, Sng JJ, Wang PXH, et al. Sodium hyaluronate in the treatment of dry eye syndrome: a systematic review and meta-analysis. Sci Rep. 2017;7(1):9013.
pubmed: 28827614
pmcid: 5567178
doi: 10.1038/s41598-017-08534-5
International Dry Eye WorkShop (2007) Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):163–78.
Hafliðadóttir SH, Juhl CB, Nielsen SM, et al. Placebo response and effect in randomized clinical trials: meta-research with focus on contextual effects. Trials. 2021;22(1):493.
pubmed: 34311793
pmcid: 8314506
doi: 10.1186/s13063-021-05454-8
Roji R, Stone P, Ricciardi F, et al. Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression. BMJ Support Palliat Care. 2020;10(4):385–94.
pubmed: 32046962
pmcid: 7691807
doi: 10.1136/bmjspcare-2019-002163
Furukawa TA. Review: placebo is better than no treatment for subjective continuous outcomes and for treatment of pain. ACP J Club. 2002;136(1):20.
pubmed: 11829561
doi: 10.7326/ACPJC-2002-136-1-020
Zhang W, Doherty M. Efficacy paradox and proportional contextual effect (PCE). Clin Immunol. 2018;186:82–6.
pubmed: 28736278
doi: 10.1016/j.clim.2017.07.018
Walach H. The efficacy paradox in randomized controlled trials of CAM and elsewhere: beware of the placebo trap. J Altern Complement Med. 2001;7(3):213–8.
pubmed: 11439833
doi: 10.1089/107555301300328070
Cho HJ, Hotopf M, Wessely S. The placebo response in the treatment of chronic fatigue syndrome: a systematic review and meta-analysis. Psychosom Med. 2005;67(2):301–13.
pubmed: 15784798
doi: 10.1097/01.psy.0000156969.76986.e0
Furukawa TA, Cipriani A, Atkinson LZ, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016;3(11):1059–66.
pubmed: 27726982
doi: 10.1016/S2215-0366(16)30307-8
Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19(1):34–40.
pubmed: 18823760
doi: 10.1016/j.euroneuro.2008.08.009
Howick J, Friedemann C, Tsakok M, et al. Are treatments more effective than placebos? A systematic review and meta-analysis. PLoS ONE. 2013;8(5):e62599.
pubmed: 23690944
pmcid: 3655171
doi: 10.1371/journal.pone.0062599
Benedetti F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol. 2008;48:33–60.
pubmed: 17666008
doi: 10.1146/annurev.pharmtox.48.113006.094711
Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008;59:565–90.
pubmed: 17550344
doi: 10.1146/annurev.psych.59.113006.095941
Colloca L, Miller FG. Harnessing the placebo effect: the need for translational research. Philos Trans R Soc Lond B Biol Sci. 2011;366(1572):1922–30.
pubmed: 21576150
pmcid: 3130404
doi: 10.1098/rstb.2010.0399
McDonald CJ, Mazzuca SA, McCabe GP Jr. How much of the placebo “effect” is really statistical regression? Stat Med. 1983;2(4):417–27.
pubmed: 6369471
doi: 10.1002/sim.4780020401
McCarney R, Warner J, Iliffe S, et al. The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol. 2007;7:30.
pubmed: 17608932
pmcid: 1936999
doi: 10.1186/1471-2288-7-30
Horin AP, Lee KM, Colloca L. Placebo effects in therapeutic outcomes. Curr Clin Pharmacol. 2014;9(2):116–22.
pubmed: 23343015
doi: 10.2174/1574884708999140101145528
Imanaka T, Sato I, Tanaka S, et al. Predictive factors for the placebo effect in clinical trials for dry eye: a pooled analysis of three clinical trials. Br J Ophthalmol. 2017;101(11):1471–4.
pubmed: 28315833
doi: 10.1136/bjophthalmol-2016-309887
International Dry Eye WorkShop (2007) Design and conduct of clinical trials: report of the Clinical Trials Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):153–62.
Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475–83.
pubmed: 24289915
doi: 10.1016/j.ophtha.2013.09.015
Kasetsuwan N, Chantaralawan K, Reinprayoon U, et al. Efficacy of topical bevacizumab 0.05% eye drops in dry eye disease: a double-masked, randomized trial. PLoS ONE. 2020;15(6):e0234186.
pubmed: 32502179
pmcid: 7274382
doi: 10.1371/journal.pone.0234186
Kawashima M, Tsuno S, Matsumoto M, et al. Hydrogen-producing milk to prevent reduction in tear stability in persons using visual display terminals. Ocul Surf. 2019;17(4):714–21.
pubmed: 31352083
doi: 10.1016/j.jtos.2019.07.008
Malhotra R, Devries DK, Luchs J, et al. Effect of OTX-101, a novel nanomicellar formulation of cyclosporine A, on corneal staining in patients with keratoconjunctivitis sicca: a pooled analysis of phase 2b/3 and phase 3 studies. Cornea. 2019;38(10):1259–65.
pubmed: 31306284
pmcid: 6749965
doi: 10.1097/ICO.0000000000001989
Choi MG, Yeo JH, Kang JW, et al. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines. Graefes Arch Clin Exp Ophthalmol. 2019;257(2):331–8.
pubmed: 30552510
doi: 10.1007/s00417-018-4194-3
Szegedi S, Scheschy U, Schmidl D, et al. Effect of single instillation of two hyaluronic acid-based topical lubricants on tear film thickness in patients with dry eye syndrome. J Ocul Pharmacol Ther. 2018;34(9):605–11.
pubmed: 30325687
doi: 10.1089/jop.2018.0069
He Y, Li J, Zhu J, et al. The improvement of dry eye after cataract surgery by intraoperative using ophthalmic viscosurgical devices on the surface of cornea: The results of a consort-compliant randomized controlled trial. Medicine (Baltimore). 2017;96(50):e8940.
doi: 10.1097/MD.0000000000008940
Toshida H, Funaki T, Ono K, et al. Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial. Drug Des Devel Ther. 2017;11:1871–9.
pubmed: 28694687
pmcid: 5491700
doi: 10.2147/DDDT.S137825
Schmidl D, Werkmeister R, Kaya S, et al. A controlled, randomized double-blind study to evaluate the safety and efficacy of chitosan-N-acetylcysteine for the treatment of dry eye syndrome. J Ocul Pharmacol Ther. 2017;33(5):375–82.
pubmed: 28441068
doi: 10.1089/jop.2016.0123
Kheirkhah A, Di Zazzo A, Satitpitakul V, et al. A pilot randomized trial on safety and efficacy of a novel topical combined inhibitor of Janus kinase 1/3 and spleen tyrosine kinase for GVHD-associated ocular surface disease. Cornea. 2017;36(7):799–804.
pubmed: 28445193
doi: 10.1097/ICO.0000000000001206
Goyal P, Jain AK, Malhotra C. Oral omega-3 fatty acid supplementation for laser in situ keratomileusis-associated dry eye. Cornea. 2017;36(2):169–75.
pubmed: 28060063
doi: 10.1097/ICO.0000000000001108
Inoue S, Kawashima M, Hisamura R, et al. Clinical evaluation of a royal jelly supplementation for the restoration of dry eye: a prospective randomized double blind placebo controlled study and an experimental mouse model. PLoS ONE. 2017;12(1):e0169069.
pubmed: 28060936
pmcid: 5217957
doi: 10.1371/journal.pone.0169069
Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). Ophthalmology. 2017;124(1):53–60.
pubmed: 28079022
doi: 10.1016/j.ophtha.2016.09.025
Chinnery HR, Naranjo Golborne C, Downie LE. Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study. Ophthalmic Physiol Opt. 2017;37(4):473–81.
pubmed: 28295445
doi: 10.1111/opo.12365
Goldstein MH, Martel JR, Sall K, et al. Multicenter Study Of A Novel Topical Interleukin-1 receptor inhibitor, isunakinra, in subjects with moderate to severe dry eye disease. Eye Contact Lens. 2017;43(5):287–96.
pubmed: 27466718
doi: 10.1097/ICL.0000000000000276
Bhargava R, Kumar P, Arora Y. Short-term omega 3 fatty acids treatment for dry eye in young and middle-aged visual display terminal users. Eye Contact Lens. 2016;42(4):231–6.
pubmed: 26322917
doi: 10.1097/ICL.0000000000000179
López-de la Rosa A, Pinto-Fraga J, Blázquez Arauzo F, et al. Safety and efficacy of an artificial tear containing 0.3% hyaluronic acid in the management of moderate-to-severe dry eye disease. Eye Contact Lens. 2017;43(6):383–8.
pubmed: 27243353
doi: 10.1097/ICL.0000000000000284
Petrov A, Perekhvatova N, Skulachev M, et al. SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model. Adv Ther. 2016;33(1):96–115.
pubmed: 26733410
pmcid: 4735228
doi: 10.1007/s12325-015-0274-5
Kawakita T, Uchino M, Fukagawa K, et al. Randomized, multicenter, double-blind study of the safety and efficacy of 1%D-3-hydroxybutyrate eye drops for dry eye disease. Sci Rep. 2016;6:20855.
pubmed: 26865350
pmcid: 4749988
doi: 10.1038/srep20855
Baek J, Doh SH, Chung SK. The effect of topical diquafosol tetrasodium 3% on dry eye after cataract surgery. Curr Eye Res. 2016;41(10):1281–5.
pubmed: 27049809
doi: 10.3109/02713683.2015.1122813
Wang L, Chen X, Hao J, et al. Proper balance of omega-3 and omega-6 fatty acid supplements with topical cyclosporine attenuated contact lens-related dry eye syndrome. Inflammopharmacology. 2016;24(6):389–96.
pubmed: 27766505
doi: 10.1007/s10787-016-0291-2
Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016;35(6):741–8.
pubmed: 27055211
pmcid: 4859202
doi: 10.1097/ICO.0000000000000803
Bhargava R, Chandra M, Bansal U, et al. A randomized controlled trial of omega 3 fatty acids in rosacea patients with dry eye symptoms. Curr Eye Res. 2016;41(10):1274–80.
pubmed: 27050028
doi: 10.3109/02713683.2015.1122810
Brzheskiy VV, Efimova EL, Vorontsova TN, et al. Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of visomitin eye drops in patients with dry eye syndrome. Adv Ther. 2015;32(12):1263–79.
pubmed: 26660938
pmcid: 4679790
doi: 10.1007/s12325-015-0273-6
Grosskreutz CL, Hockey HU, Serra D, et al. Dry eye signs and symptoms persist during systemic neutralization of IL-1β by canakinumab or IL-17A by secukinumab. Cornea. 2015;34(12):1551–6.
pubmed: 26418434
pmcid: 4633966
doi: 10.1097/ICO.0000000000000627
Bhargava R, Kumar P. Oral omega-3 fatty acid treatment for dry eye in contact lens wearers. Cornea. 2015;34(4):413–20.
pubmed: 25719253
doi: 10.1097/ICO.0000000000000386
Craig JP, Chen YH, Turnbull PR. Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2015;56(3):1965–70.
pubmed: 25678687
doi: 10.1167/iovs.14-15764
Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491–6.
pubmed: 25826322
doi: 10.1097/ICO.0000000000000379
Kaya S, Schmidl D, Schmetterer L, et al. Effect of hyaluronic acid on tear film thickness as assessed with ultra-high resolution optical coherence tomography. Acta Ophthalmol. 2015;93(5):439–43.
pubmed: 25601227
doi: 10.1111/aos.12647
Kawakita T, Kawabata F, Tsuji T, et al. Effects of dietary supplementation with fish oil on dry eye syndrome subjects: randomized controlled trial. Biomed Res. 2013;34(5):215–20.
pubmed: 24190233
doi: 10.2220/biomedres.34.215
Sheppard JD Jr, Singh R, McClellan AJ, et al. Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial. Cornea. 2013;32(10):1297–304.
pubmed: 23884332
doi: 10.1097/ICO.0b013e318299549c
Kangari H, Eftekhari MH, Sardari S, et al. Short-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology. 2013;120(11):2191–6.
pubmed: 23642375
doi: 10.1016/j.ophtha.2013.04.006
Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153(6):1050–60.
pubmed: 22330307
doi: 10.1016/j.ajo.2011.11.003
Larmo PS, Järvinen RL, Setälä NL, et al. Oral sea buckthorn oil attenuates tear film osmolarity and symptoms in individuals with dry eye. J Nutr. 2010;140(8):1462–8.
pubmed: 20554904
doi: 10.3945/jn.109.118901
Järvinen RL, Larmo PS, Setälä NL, et al. Effects of oral sea buckthorn oil on tear film Fatty acids in individuals with dry eye. Cornea. 2011;30(9):1013–9.
pubmed: 21832964
doi: 10.1097/ICO.0b013e3182035ad9
Lee JH, Han K, Kim TH, et al. Acupuncture for dry eye syndrome after refractive surgery: A randomized controlled pilot trial. Integr Med Res. 2021;10(1):100456.
pubmed: 32904133
doi: 10.1016/j.imr.2020.100456
Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea. 2011;30(3):308–14.
pubmed: 21045648
doi: 10.1097/ICO.0b013e3181f22e03
Villani E, Laganovska G, Viola F, et al. A multicenter, double-blind, parallel group, placebo-controlled clinical study to examine the safety and efficacy of T-Clair SPHP700-3 in the management of mild to moderate dry eye in adults. Cornea. 2011;30(3):265–8.
pubmed: 21099417
doi: 10.1097/ICO.0b013e3181e9aab8
Vogel R, Crockett RS, Oden N, et al. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (Vismed, Rejena). Am J Ophthalmol. 2010;149(4):594–601.
pubmed: 20346777
doi: 10.1016/j.ajo.2009.09.023
Avni I, Garzozi HJ, Barequet IS, et al. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. Ophthalmology. 2010;117(7):1287–93.
pubmed: 20304499
doi: 10.1016/j.ophtha.2009.11.029
Drouault-Holowacz S, Bieuvelet S, Burckel A, et al. Antioxidants intake and dry eye syndrome: a crossover, placebo-controlled, randomized trial. Eur J Ophthalmol. 2009;19(3):337–42.
pubmed: 19396775
doi: 10.1177/112067210901900302
Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye. 2008;31(3):141–6 (quiz 70).
pubmed: 18313350
doi: 10.1016/j.clae.2007.12.001
Mah FS, O’Brien T, Kim T, et al. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Curr Med Res Opin. 2008;24(2):441–7.
pubmed: 18167176
doi: 10.1185/030079908X261078
Johnson ME, Murphy PJ, Boulton M. Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye. Graefes Arch Clin Exp Ophthalmol. 2006;244(1):109–12.
pubmed: 15983814
doi: 10.1007/s00417-005-0028-1
Selek H, Unlü N, Orhan M, et al. Evaluation of retinoic acid ophthalmic emulsion in dry eye. Eur J Ophthalmol. 2000;10(2):121–7.
pubmed: 10887922
doi: 10.1177/112067210001000205
Aragona P, Papa V, Micali A, et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002;86(2):181–4.
pubmed: 11815344
pmcid: 1771021
doi: 10.1136/bjo.86.2.181
Asbell PA, Maguire MG, Pistilli M, et al. n-3 fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018;378(18):1681–90.
pubmed: 29652551
doi: 10.1056/NEJMoa1709691
Katz J, West KP Jr, Khatry SK, et al. Impact of vitamin A supplementation on prevalence and incidence of xerophthalmia in Nepal. Invest Ophthalmol Vis Sci. 1995;36(13):2577–83.
pubmed: 7499080
Shokoohi-Rad S, Javaheri SZH, Malekabad FZ, et al. Effects of preoperative doses of betamethasone acetate 0.1% on dry eye control after cataract surgery. Indian J Ophthalmol. 2020;68(3):450–4.
pubmed: 32057000
pmcid: 7043147
doi: 10.4103/0301-4738.278367
Xue AL, Wang MTM, Ormonde SE, et al. Randomised double-masked placebo-controlled trial of the cumulative treatment efficacy profile of intense pulsed light therapy for meibomian gland dysfunction. Ocul Surf. 2020;18(2):286–97.
pubmed: 32007523
doi: 10.1016/j.jtos.2020.01.003
Chang KC, Oh JY, In YS, et al. Preliminary effects of oral uridine on the ocular surface in dry eye patients. J Korean Med Sci. 2009;24(4):701–7.
pubmed: 19654956
pmcid: 2719204
doi: 10.3346/jkms.2009.24.4.701
Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444–57.
pubmed: 15364229
doi: 10.1016/j.ajo.2004.04.052
Willen CM, McGwin G, Liu B, et al. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. Eye Contact Lens. 2008;34(1):43–5.
pubmed: 18180683
doi: 10.1097/ICL.0b013e3180676d44
Semba RD, Muhilal M, West Jr KP, et al. Hyporetinolemia and acute phase proteins in children with and without xerophthalmia. Am J Clin Nutr. 2000;72(1):146–53.
Hussain M, Shtein RM, Pistilli M, et al. The Dry Eye Assessment and Management (DREAM) extension study—a randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease. Ocul Surf. 2020;18(1):47–55.
pubmed: 31425752
doi: 10.1016/j.jtos.2019.08.002
Epitropoulos AT, Donnenfeld ED, Shah ZA, et al. Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes. Cornea. 2016;35(9):1185–91.
pubmed: 27442314
pmcid: 4975557
doi: 10.1097/ICO.0000000000000940
Oleñik A, Jiménez-Alfaro I, Alejandre-Alba N, et al. A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction. Clin Interv Aging. 2013;8:1133–8. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence . Accessed on March 2022.
pubmed: 24039409
pmcid: 3770496
doi: 10.2147/CIA.S48955
Howick J CI, Glasziou P, Greenhalgh T, et al. The 2011 Oxford CEBM levels of evidence. Oxford Centre for Evidence-Based Medicine; 2011. https://urldefense.com/v3/__ , https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence . Accessed on March 2022.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
pubmed: 33782057
pmcid: 8005924
doi: 10.1136/bmj.n71
Walt JRM, Stern K. Evaluating the functional impact of dry eye: the ocular surface disease Index. Drug Inf J. 1997;31:1436.
Cho P, Leung L, Lam A, et al. Tear break-up time: clinical procedures and their effects. Ophthalmic Physiol Opt. 1998;18(4):319–24.
pubmed: 9829104
doi: 10.1046/j.1475-1313.1998.00385.x
Cho P, Yap M. Schirmer test. I. A review. Optom Vis Sci. 1993;70(2):152–6.
pubmed: 8446379
doi: 10.1097/00006324-199302000-00011
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
pubmed: 15205295
doi: 10.1136/bmj.328.7454.1490
Shin MS, Kim JI, Lee MS, et al. Acupuncture for treating dry eye: a randomized placebo-controlled trial. Acta Ophthalmol. 2010;88(8):e328–33.
pubmed: 21070615
doi: 10.1111/j.1755-3768.2010.02027.x
Sullivan DA, Rocha EM, Aragona P, et al. TFOS DEWS II sex, gender, and hormones report. Ocul Surf. 2017;15(3):284–333.
pubmed: 28736336
doi: 10.1016/j.jtos.2017.04.001
Truong S, Cole N, Stapleton F, et al. Sex hormones and the dry eye. Clin Exp Optom. 2014;97(4):324–36.
pubmed: 24689906
doi: 10.1111/cxo.12147
Artus M, van der Windt D, Jordan KP, et al. The clinical course of low back pain: a meta-analysis comparing outcomes in randomised clinical trials (RCTs) and observational studies. BMC Musculoskelet Disord. 2014;15:68.
pubmed: 24607083
pmcid: 4007531
doi: 10.1186/1471-2474-15-68
Seitzman GD, Lietman TM. Dry eye research-still regressing? Ophthalmology. 2019;126(2):192–4.
pubmed: 30683176
doi: 10.1016/j.ophtha.2018.09.046
Colloca L. The Placebo effect in pain therapies. Annu Rev Pharmacol Toxicol. 2019;59:191–211.
pubmed: 30216744
doi: 10.1146/annurev-pharmtox-010818-021542
Leuchter AF, Hunter AM, Tartter M, et al. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry. 2014;205(6):443–9.
pubmed: 25213159
pmcid: 4248233
doi: 10.1192/bjp.bp.113.140343
Kemeny ME, Rosenwasser LJ, Panettieri RA, et al. Placebo response in asthma: a robust and objective phenomenon. J Allergy Clin Immunol. 2007;119(6):1375–81.
pubmed: 17451796
doi: 10.1016/j.jaci.2007.03.016
Avins AL, Pressman A, Ackerson L, et al. Placebo adherence and its association with morbidity and mortality in the studies of left ventricular dysfunction. J Gen Intern Med. 2010;25(12):1275–81.
pubmed: 20706875
pmcid: 2988150
doi: 10.1007/s11606-010-1477-8
Colloca L, Barsky AJ. Placebo and nocebo effects. N Engl J Med. 2020;382(6):554–61.
pubmed: 32023375
doi: 10.1056/NEJMra1907805
Chen X, Zou K, Abdullah N, et al. The placebo effect and its determinants in fibromyalgia: meta-analysis of randomised controlled trials. Clin Rheumatol. 2017;36(7):1623–30.
pubmed: 28299460
pmcid: 5486479
doi: 10.1007/s10067-017-3595-8
Eippert F, Bingel U, Schoell ED, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron. 2009;63(4):533–43.
pubmed: 19709634
doi: 10.1016/j.neuron.2009.07.014
Benedetti F, Amanzio M, Rosato R, et al. Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nat Med. 2011;17(10):1228–30.
pubmed: 21963514
doi: 10.1038/nm.2435
Benedetti F, Colloca L, Torre E, et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci. 2004;7(6):587–8.
pubmed: 15146189
doi: 10.1038/nn1250
Kessner S, Sprenger C, Wrobel N, et al. Effect of oxytocin on placebo analgesia: a randomized study. JAMA. 2013;310(16):1733–5.
pubmed: 24150470
doi: 10.1001/jama.2013.277446
Colloca L, Pine DS, Ernst M, et al. Vasopressin boosts placebo analgesic effects in women: a randomized trial. Biol Psychiatry. 2016;79(10):794–802.
pubmed: 26321018
doi: 10.1016/j.biopsych.2015.07.019
Petrovic P, Kalso E, Petersson KM, et al. Placebo and opioid analgesia—imaging a shared neuronal network. Science. 2002;295(5560):1737–40.
pubmed: 11834781
doi: 10.1126/science.1067176
Kheirkhah A, Crnej A, Ren A, et al. Patients’ perceived treatment effectiveness in dry eye disease. Cornea. 2017;36(8):893–7.
pubmed: 28481835
doi: 10.1097/ICO.0000000000001216
Pollo A, Amanzio M, Arslanian A, et al. Response expectancies in placebo analgesia and their clinical relevance. Pain. 2001;93(1):77–84.
pubmed: 11406341
doi: 10.1016/S0304-3959(01)00296-2
Asbell PA, Maguire MG, Peskin E, et al. Dry Eye Assessment and Management (DREAM©) Study: study design and baseline characteristics. Contemp Clin Trials. 2018;71:70–9.
pubmed: 29883769
pmcid: 7250048
doi: 10.1016/j.cct.2018.06.002
Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389(10088):2473–81.
pubmed: 28476288
doi: 10.1016/S0140-6736(17)31075-9
Rosenzweig P, Brohier S, Zipfel A. The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clin Pharmacol Ther. 1993;54(5):578–83.
pubmed: 8222500
doi: 10.1038/clpt.1993.190
Benedetti F, Amanzio M, Vighetti S, et al. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci. 2006;26(46):12014–22.
pubmed: 17108175
pmcid: 6674855
doi: 10.1523/JNEUROSCI.2947-06.2006
Bramer WM, Rethlefsen ML, Kleijnen J, et al. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. Syst Rev. 2017;6(1):245.
pubmed: 29208034
pmcid: 5718002
doi: 10.1186/s13643-017-0644-y
Lee MS, Shin BC, Choi TY, et al. Acupuncture for treating dry eye: a systematic review. Acta Ophthalmol. 2011;89(2):101–6.
pubmed: 20337604
doi: 10.1111/j.1755-3768.2009.01855.x
Park J, White A, Stevinson C, et al. Validating a new non-penetrating sham acupuncture device: two randomised controlled trials. Acupunct Med. 2002;20(4):168–74.
pubmed: 12512790
doi: 10.1136/aim.20.4.168
Linde K, Niemann K, Meissner K. Are sham acupuncture interventions more effective than (other) placebos? A re-analysis of data from the Cochrane review on placebo effects. Forsch Komplementmed. 2010;17(5):259–64.
pubmed: 20980765
doi: 10.1159/000320374